News and Analysis

You’ve more than likely heard of Ozempic, the diabetes drug made by Danish healthcare giant Novo Nordisk and hailed as a miracle weight-loss treatment. GLP-1 weight-loss and...

Analyst Weekly, December 8, 2025 A BOJ hiking cycle could be 2026’s biggest macro plot twist. After years of snoozing near zero, Japan’s 10-year government bond yield (JGB)...

The Daily Breakdown digs into Uber's business, its turn to profitability, the stock's valuation, and the risks that it faces in its industry. Before we dive in, let’s make sure...

For writer and How I Fund This founder Jessie Leong, the hardest step wasn't learning the jargon, it was finding the confidence to start. Now she’s demanding equal access to...

The Daily Breakdown takes a closer look at silver prices, which have doubled in 2025, then dives into Salesforce's earnings beat. Before we dive in, let’s make sure you’re set...

The Daily Breakdown takes a closer look at the latest Ethereum upgrade and its technical setup, and dives into Ondo and Worldcoin. Before we dive in, let’s make sure you’re set...

Novo Nordisk ($NVO) has been one of the most influential healthcare companies thanks to its obesity drugs Ozempic and Wegovy. These products changed the weight loss industry,...

MicroStrategy ($MSTR): The Corporate Bitcoin Treasury Pioneer MicroStrategy, once primarily an enterprise analytics software firm, has radically reinvented itself as the world's...

Summary points: The sharp stock price drop after a solid earnings report is an entry or accumulation opportunity; Fortinet, despite a cautious guidance due to macro...

Investing is often seen as a game of numbers, charts, ratios, and probabilities, but at its core, investing is really a process of decision-making. And good...